Rising US measles cases spur drug development efforts

The United States is experiencing its highest number of measles cases in decades amid declining vaccination rates. Researchers have begun developing treatments for the virus and for vulnerable individuals.

Up until recently, the effectiveness of measles vaccination meant there was little medical or financial incentive to create treatments for the disease.

As cases climb, scientists are now working on drugs to assist those who become infected or face higher risks from the virus.

The shift reflects changing public health conditions in the country.

Related Articles

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
Image generated by AI

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

Reported by AI Image generated by AI Fact checked

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Researchers at Georgia State University have developed an oral drug that stopped a measles-like virus from transmitting between ferrets via air or contact. The treatment worked when given before or after exposure and shortened illness duration.

Reported by AI

The São Paulo State Health Department confirmed two new measles cases in the state capital on Tuesday (30), bringing the total infections recorded in the state in 2026 to seven.

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Reported by AI

The Ministry of Health issued an epidemiological alert due to the unusual rise in Influenza B cases during the current period, according to the weekly Winter Campaign 2026 report.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline